To explain this, we can hypothesize that, as part of an intricate network of transforming mechanisms in melanoma, this disease simultaneously uses multiple oncogenic mechanisms, such as, for example, PI3K, MET and GNAQ [28, 29], that, along with MAPK signaling, act as mechanistic drivers of the disease and promote progression or resistance to therapy. The gene discussed is MET; the disease is melanoma.